Updates on current advances in gene therapy

West Indian Medical Journal

Volumn 60, Issue 2, 2012, Pages 188-194

  Tani, Jowy ^a   Faustine, ^b   Sufian, Jomiany Tani ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Adenovirus; Gene therapy; Nonviral vectors; Oncolytic viruses; Retrovirus; Suicide gene therapy

Indexed keywords

ADENOVIRUS VECTOR; ALPHA 1 ANTITRYPSIN; CYTOCHROME P450 2B; CYTOSINE DEAMINASE; FIBROBLAST GROWTH FACTOR; FLUCYTOSINE; GENDICINE; INORGANIC NANOPARTICLE; LENTIVIRUS VECTOR; LIPOPLEX; NANOPARTICLE; NERVE GROWTH FACTOR; ONCOLYTIC VIRUS; ORNITHINE CARBAMOYLTRANSFERASE; POLYPLEX; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENO ASSOCIATED VIRUS; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CHRONIC GRANULOMATOUS DISEASE; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; EPIDERMOLYSIS BULLOSA; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; LEBER CONGENITAL AMAUROSIS; LYSOSOME STORAGE DISEASE; MUSCULAR DYSTROPHY; NONVIRAL GENE THERAPY; ONCOLYTIC VIROTHERAPY; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PARKINSON DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PSEUDOTYPE VIRUS; SEVERE COMBINED IMMUNODEFICIENCY; SUICIDE GENE THERAPY; VIRUS;

EID: 84857813981     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M et al. T lymphocyte-directed gene therapy for ADASCID: Initial trial results after 4 years. Science 1995; 270: 475-80.
2. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 2009; 361: 725-7.
3. AiutiA, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L et al. Gene therapy for immunodeficiency due to adenosine deaminase Deficiency. N Engl J Med 2009; 360: 447-58.
4. US Food and DrugAdministration Homepage [Internet]. Silver Spring: United States Food and DrugAdministration; c2009 [updated 2009Aug 13; cited 2010 Mar 30]. Cellular & Gene Therapy Products; [about 3 screens]. Available from: http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm
5. Gene therapy clinical trials worldwide [Internet]. Chichester: The Journal of Gene Medicine; c2009 [updated 2009 Dec; cited 2010 Mar 30]. Vectors used in gene therapy clinical trials; [about 3 screens]. Available from: http://www.wiley.co.uk/genmed/clinical/
6. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007 117: 2083-6.
7. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007 36: 71-80.
8. Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15: 817-22.
9. Frecha C, Szécsi J, Cosset FL, Verhoeyen E. Strategies for targeting lentiviral vectors. Curr Gene Ther 2008; 8: 449-60.
10. Burton EA, Fink DJ, Glorioso JC. Gene delivery using herpes simplex virus vectors. DNA Cell Biol 2002; 21: 915-36.
11. Al-Dosari MS, Gao X. Nonviral Gene Delivery: Principle, Limitations, and Recent Progress. AAPS J 2009; 11: 671-81.
12. Palmer TD, Rosman GJ, Osborne WR, Miller AD. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc NatlAcad Sci USA1991; 88: 1330-4.
13. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-72.
14. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-93.
15. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-7.
16. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-3.
17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 17; 302: 415-9.
18. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-42.
19. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquiredsomatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-50.
20. Modlich U, Bohne J, Schmidt M, Von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-53.
21. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumour-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-96.
22. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 2007; 318: 1296-9.
23. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 2008; 16: 718-25.
24. Chung JH, Whiteley M, Felsenfeld G. A 5' element of the chicken betaglobin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993; 74: 505-14.
25. Hauswirth WW, Aleman TS, Kaushal S, Cideciyan AV, Schwartz SB, Wang L et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19: 979-90.
26. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358: 2240-8.
27. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of Single gene disorders: results of a phase I clinical trial. Hum Gene Ther 2006; 17: 167-76.
28. Mancuso K, Hauswirth WW, Li Q, Connor TB, Kuchenbecker JA, Mauck MC et al. Gene therapy for red-green colour blindness in adult primates. Nature 2009; 8: 784-7.
29. Stedman H, Wilson JM, Finke R, Kleckner AL, Mendell J. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. J Hum Gene Ther 2000; 11: 777-90.
30. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al. Repeated adeno-associated virus serotype 2 aerosolmediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509-21.
31. Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, PoirrierA et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alpha(1)-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17: 1177-86.
32. Bloch J, Bachoud-Lévi AC, Déglon N, Lefaucheur JP, Winkel L, Palfi S et al. Neuroprotective gene therapy for Huntington's disease using polymer encapsulated cells engineered to secrete human CNTF: results of a phase I study. Hum Gene Ther 2004; 15: 968-75.
33. Sands MS, Davidson BL. Gene therapy for lysosomal storage diseases. Mol Ther 2006; 13: 839-49.
34. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS/EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-9.
35. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-75.
36. Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006; 12: 1397-402.
37. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ et al. Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-7.
38. Gene therapy clinical trials worldwide [Internet]. Chichester: The Journal of Gene Medicine; c2009 [updated 2009 Dec; cited 2010 Mar 30]. Indications addressed by gene therapy clinical trials; [about 2 screens]. Available from: http://www.wiley.co.uk/genmed/clinical/.
39. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D et al. A phase I trial of intratumoural administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16: 627-32.
40. Dobrikova EY, Broadt T, Poiley-Nelson J, Yang X, Soman G, Giardina S et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol Ther 2008; 16: 1865-72.
41. Peng Z. Current status of gendicine in China: recombinant human Adp53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-27.
42. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol 2004; 22: 3-4.
43. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000; 11: 2389-401.
44. Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 2005; 11: 1512-20.
45. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005; 17: 163-9.
46. Shi M, Su L, Hao S, Guo X, Xiang J. Fusion hybrid of dendritic cells and engineered tumour cells expressing interleukin-12 induces type 1 immune responses against tumour. Tumouri 2005; 91: 531-8.
47. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
48. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45: 982-8.
49. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006; 13: 1503-11.
50. Mäkinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, doubleblinded phase II study. Mol Ther 2002; 6: 127-33.
51. Rajagopalan S, Mohler III ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-8.
52. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA et al. Safety and tolerability of AAV-GAD gene therapy for Parkinson's disease: an open-label, phase I trial. Lancet. 2007; 369: 2097-105.
53. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell III J, Gasmi M et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006; 60: 706-15.
54. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J et al. Long-term clinical improvement in MPTPlesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006; 14: 564-70.
55. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Nontropic actions of neurotrophins: subcortical nerve growth factor gene delivery reversesage-related degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA 2001; 98: 1941-6.
56. Arvanitakis Z, Tuszynski MH, Bakay R, Arends D, Potkin S, Bartus R et al. Interim data from a phase 1 clinical trial of AAV-NGF (CERE-110) gene delivery in Alzheimers disease. Abstr Amer Acad Neurol 2007; 05. 071
57. Nagahara AH, Bernot T, Moseanko R, Brignolo L, Blesch A, Conner JM et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp Neurol 2009; 215: 153-9.
58. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P et al. A clinical trial of retroviral-mediated transfer of a Rev-responsive element decoy gene into CD34 cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 279-87.
59. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X et al. Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS. 2006; 103: 17372-7.